These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12419752)

  • 1. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time.
    Foss Abrahamsen A; Andersen A; Nome O; Jacobsen AB; Holte H; Foss Abrahamsen J; Kvaløy S
    Ann Oncol; 2002 Nov; 13(11):1786-91. PubMed ID: 12419752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
    van Leeuwen FE; Klokman WJ; Hagenbeek A; Noyon R; van den Belt-Dusebout AW; van Kerkhoff EH; van Heerde P; Somers R
    J Clin Oncol; 1994 Feb; 12(2):312-25. PubMed ID: 8113838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.
    Mauch PM; Kalish LA; Marcus KC; Coleman CN; Shulman LN; Krill E; Come S; Silver B; Canellos GP; Tarbell NJ
    Blood; 1996 May; 87(9):3625-32. PubMed ID: 8611686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age.
    Abrahamsen JF; Andersen A; Hannisdal E; Nome O; Abrahamsen AF; Kvaløy S; Høst H
    J Clin Oncol; 1993 Feb; 11(2):255-61. PubMed ID: 8426202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
    Swerdlow AJ; Barber JA; Horwich A; Cunningham D; Milan S; Omar RZ
    Br J Cancer; 1997; 75(1):116-23. PubMed ID: 9000608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hodgkin's disease: study of treatment intensities and incidences of second malignancies.
    Rodriguez MA; Fuller LM; Zimmerman SO; Allen PK; Brown BW; Munsell MF; Hagemeister FB; McLaughlin P; Velasquez WS; Swan F
    Ann Oncol; 1993 Feb; 4(2):125-31. PubMed ID: 8448080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second malignancies after Hodgkin's disease: the Munich experience.
    Munker R; Grützner S; Hiller E; Aydemir U; Enne W; Dietzfelbinger H; Busch M; Haas R; Emmerich B; Schmidt M; Dühmke E; Hölzel D; Wilmanns W
    Ann Hematol; 1999 Dec; 78(12):544-54. PubMed ID: 10647878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital.
    Cellai E; Magrini SM; Masala G; Alterini R; Costantini AS; Rigacci L; Olmastroni L; Papi MG; Spediacci MA; Innocenti F; Bellesi G; Ferrini PR; Biti G
    Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1327-37. PubMed ID: 11286841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.
    van Leeuwen FE; Klokman WJ; Veer MB; Hagenbeek A; Krol AD; Vetter UA; Schaapveld M; van Heerde P; Burgers JM; Somers R; Aleman BM
    J Clin Oncol; 2000 Feb; 18(3):487-97. PubMed ID: 10653864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
    Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of second cancers in patients treated for Hodgkin's disease.
    Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P
    J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.
    Sanna G; Lorizzo K; Rotmensz N; Bagnardi V; Cinieri S; Colleoni M; Nolè F; Goldhirsch A
    Ann Oncol; 2007 Feb; 18(2):288-92. PubMed ID: 17088328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second solid malignancies after combined modality therapy for Hodgkin's disease.
    Doria R; Holford T; Farber LR; Prosnitz LR; Cooper DL
    J Clin Oncol; 1995 Aug; 13(8):2016-22. PubMed ID: 7636543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group.
    Bhatia S; Yasui Y; Robison LL; Birch JM; Bogue MK; Diller L; DeLaat C; Fossati-Bellani F; Morgan E; Oberlin O; Reaman G; Ruymann FB; Tersak J; Meadows AT;
    J Clin Oncol; 2003 Dec; 21(23):4386-94. PubMed ID: 14645429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.
    Swerdlow AJ; Douglas AJ; Hudson GV; Hudson BV; Bennett MH; MacLennan KA
    BMJ; 1992 May; 304(6835):1137-43. PubMed ID: 1392790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease.
    Beaty O; Hudson MM; Greenwald C; Luo X; Fang L; Wilimas JA; Thompson EI; Kun LE; Pratt CB
    J Clin Oncol; 1995 Mar; 13(3):603-9. PubMed ID: 7884422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.
    Swerdlow AJ; Barber JA; Hudson GV; Cunningham D; Gupta RK; Hancock BW; Horwich A; Lister TA; Linch DC
    J Clin Oncol; 2000 Feb; 18(3):498-509. PubMed ID: 10653865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
    Moser EC; Noordijk EM; van Leeuwen FE; Baars JW; Thomas J; Carde P; Meerwaldt JH; van Glabbeke M; Kluin-Nelemans HC
    Haematologica; 2006 Nov; 91(11):1481-8. PubMed ID: 17043014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease.
    van Leeuwen FE; Somers R; Taal BG; van Heerde P; Coster B; Dozeman T; Huisman SJ; Hart AA
    J Clin Oncol; 1989 Aug; 7(8):1046-58. PubMed ID: 2754447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.